| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
The natural history of nonalcoholic fatty liver disease: a population-based cohort study.
|
Gastroenterology
|
2005
|
15.74
|
|
2
|
Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis.
|
Gastroenterology
|
2003
|
4.84
|
|
3
|
The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies.
|
J Hepatol
|
2005
|
4.65
|
|
4
|
Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study.
|
Am J Gastroenterol
|
2008
|
3.23
|
|
5
|
Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial.
|
Hepatology
|
2004
|
2.98
|
|
6
|
The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study.
|
Hepatology
|
2011
|
2.86
|
|
7
|
Nonalcoholic fatty liver disease.
|
CMAJ
|
2005
|
2.56
|
|
8
|
Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease.
|
J Hepatol
|
2005
|
2.46
|
|
9
|
Utility of a new model to diagnose an alcohol basis for steatohepatitis.
|
Gastroenterology
|
2006
|
2.25
|
|
10
|
Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis.
|
Am J Gastroenterol
|
2004
|
2.11
|
|
11
|
Prevalence and predictors of esophageal varices in patients with primary sclerosing cholangitis.
|
Hepatology
|
2004
|
2.09
|
|
12
|
NAFLD in children: a prospective clinical-pathological study and effect of lifestyle advice.
|
Hepatology
|
2006
|
2.06
|
|
13
|
Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial.
|
Hepatology
|
2008
|
2.02
|
|
14
|
The prevalence of autoantibodies and autoimmune hepatitis in patients with nonalcoholic Fatty liver disease.
|
Am J Gastroenterol
|
2004
|
1.92
|
|
15
|
The natural history of small-duct primary sclerosing cholangitis.
|
Gastroenterology
|
2008
|
1.92
|
|
16
|
Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial.
|
Hepatology
|
2009
|
1.90
|
|
17
|
Liver transplantation for the treatment of liver metastases from neuroendocrine tumors: an analysis of the UNOS database.
|
Arch Surg
|
2011
|
1.78
|
|
18
|
Low circulating levels of dehydroepiandrosterone in histologically advanced nonalcoholic fatty liver disease.
|
Hepatology
|
2008
|
1.70
|
|
19
|
Primary biliary cirrhosis: an infectious disease caused by Chlamydia pneumoniae?
|
J Hepatol
|
2004
|
1.65
|
|
20
|
The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis.
|
Dig Dis Sci
|
2005
|
1.63
|
|
21
|
Long-term mortality in nonalcoholic fatty liver disease: is liver histology of any prognostic significance?
|
Hepatology
|
2010
|
1.60
|
|
22
|
Overlap of autoimmune hepatitis and primary biliary cirrhosis: an evaluation of a modified scoring system.
|
Am J Gastroenterol
|
2002
|
1.58
|
|
23
|
A pilot trial of pentoxifylline in nonalcoholic steatohepatitis.
|
Am J Gastroenterol
|
2004
|
1.56
|
|
24
|
Noninvasive evaluation of NAFLD.
|
Nat Rev Gastroenterol Hepatol
|
2013
|
1.49
|
|
25
|
Vitamins E and C for the treatment of NASH: duplication of results but lack of demonstration of efficacy.
|
Am J Gastroenterol
|
2003
|
1.48
|
|
26
|
Mycophenolate mofetil for the treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid.
|
J Clin Gastroenterol
|
2005
|
1.48
|
|
27
|
PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways.
|
Anticancer Res
|
2010
|
1.43
|
|
28
|
Recurrent idiopathic hepatitis: a new entity?
|
J Clin Gastroenterol
|
2003
|
1.38
|
|
29
|
Nonalcoholic steatohepatitis in children: a multicenter clinicopathological study.
|
Hepatology
|
2009
|
1.37
|
|
30
|
Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study.
|
Am J Gastroenterol
|
2010
|
1.37
|
|
31
|
Tumor necrosis factor-alpha and transforming growth factor-beta reflect severity of liver damage in primary biliary cirrhosis.
|
J Gastroenterol Hepatol
|
2002
|
1.33
|
|
32
|
Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunction.
|
Hepatology
|
2004
|
1.33
|
|
33
|
Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease.
|
Liver Int
|
2005
|
1.27
|
|
34
|
The Framingham risk score and heart disease in nonalcoholic fatty liver disease.
|
Liver Int
|
2012
|
1.15
|
|
35
|
PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation.
|
J Surg Res
|
2011
|
1.15
|
|
36
|
Abnormal hepatic biochemistries in patients with inflammatory bowel disease.
|
Am J Gastroenterol
|
2006
|
1.13
|
|
37
|
Diagnosing steatohepatitis and predicting liver-related mortality in patients with NAFLD: two distinct concepts.
|
Hepatology
|
2011
|
1.12
|
|
38
|
Chronological development of elevated aminotransferases in a nonalcoholic population.
|
Hepatology
|
2005
|
1.12
|
|
39
|
Is there a role for liver biopsy in primary sclerosing cholangitis?
|
Am J Gastroenterol
|
2003
|
1.10
|
|
40
|
Secondary sclerosing cholangitis: a comparison to primary sclerosing cholangitis.
|
Am J Gastroenterol
|
2005
|
1.10
|
|
41
|
The evaluation of hepatic fibrosis scores in children with nonalcoholic fatty liver disease.
|
Dig Dis Sci
|
2014
|
1.07
|
|
42
|
Primary sclerosing cholangitis in children: a long-term follow-up study.
|
Hepatology
|
2003
|
1.07
|
|
43
|
Cost-minimization analysis of MRC versus ERCP for the diagnosis of primary sclerosing cholangitis.
|
Hepatology
|
2004
|
1.06
|
|
44
|
Can NASH be diagnosed, graded, and staged noninvasively?
|
Clin Liver Dis
|
2012
|
1.05
|
|
45
|
Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial.
|
Hepatology
|
2005
|
1.05
|
|
46
|
When is liver biopsy needed in the diagnosis of primary biliary cirrhosis?
|
Clin Gastroenterol Hepatol
|
2003
|
1.00
|
|
47
|
Values and limitations of serum aminotransferases in clinical trials of nonalcoholic steatohepatitis.
|
Liver Int
|
2006
|
0.99
|
|
48
|
Prevalence and indicators of portal hypertension in patients with nonalcoholic fatty liver disease.
|
Clin Gastroenterol Hepatol
|
2012
|
0.99
|
|
49
|
Overlap of autoimmune hepatitis and primary biliary cirrhosis: long-term outcomes.
|
Am J Gastroenterol
|
2007
|
0.99
|
|
50
|
Hepatitis C and steatosis.
|
Arch Med Res
|
2007
|
0.98
|
|
51
|
Role of liver biopsy and serum markers of liver fibrosis in non-alcoholic fatty liver disease.
|
Clin Liver Dis
|
2007
|
0.98
|
|
52
|
Light to moderate alcohol consumption is associated with lower frequency of hypertransaminasemia.
|
Am J Gastroenterol
|
2007
|
0.97
|
|
53
|
Cholangiocarcinoma in young individuals with and without primary sclerosing cholangitis.
|
Am J Gastroenterol
|
2007
|
0.94
|
|
54
|
Non-alcoholic fatty liver disease.
|
Scand J Gastroenterol
|
2007
|
0.94
|
|
55
|
Hepatic stellate cells and fibrosis progression in patients with nonalcoholic fatty liver disease.
|
Clin Gastroenterol Hepatol
|
2005
|
0.93
|
|
56
|
Varices in early histological stage primary biliary cirrhosis.
|
J Clin Gastroenterol
|
2011
|
0.89
|
|
57
|
Relations of steatosis type, grade, and zonality to histological features in pediatric nonalcoholic fatty liver disease.
|
J Pediatr Gastroenterol Nutr
|
2011
|
0.89
|
|
58
|
The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment.
|
Anticancer Res
|
2012
|
0.88
|
|
59
|
PKI-587 and sorafenib alone and in combination on inhibition of liver cancer stem cell proliferation.
|
J Surg Res
|
2013
|
0.86
|
|
60
|
The effect of the metabolic syndrome, hepatic steatosis and steatohepatitis on liver fibrosis in hereditary hemochromatosis.
|
Liver Int
|
2006
|
0.84
|
|
61
|
Clinical trials: Trial design in NASH--realities and challenges.
|
Nat Rev Gastroenterol Hepatol
|
2011
|
0.83
|
|
62
|
Raloxifene improves bone mass in osteopenic women with primary biliary cirrhosis: results of a pilot study.
|
Liver Int
|
2005
|
0.83
|
|
63
|
Risk factors for venous thromboembolism in patients with chronic liver disease.
|
Ann Pharmacother
|
2013
|
0.83
|
|
64
|
Association of primary biliary cirrhosis and rheumatoid arthritis.
|
J Clin Rheumatol
|
2003
|
0.83
|
|
65
|
Cholangiocarcinoma in pregnancy: a case report.
|
J Obstet Gynaecol Res
|
2008
|
0.83
|
|
66
|
Safety and efficacy of estrogen therapy in preventing bone loss in primary biliary cirrhosis.
|
Am J Gastroenterol
|
2003
|
0.83
|
|
67
|
Clinical predictors for hepatocellular carcinoma in patients with primary biliary cirrhosis.
|
Clin Gastroenterol Hepatol
|
2006
|
0.81
|
|
68
|
Mycophenolate mofetil for the treatment of primary sclerosing cholangitis.
|
Am J Gastroenterol
|
2005
|
0.81
|
|
69
|
A pilot trial of high-dose ursodeoxycholic acid in nonalcoholic steatohepatitis.
|
Hepatol Int
|
2010
|
0.80
|
|
70
|
Impact of inflammatory bowel disease and ursodeoxycholic acid therapy on small-duct primary sclerosing cholangitis.
|
Hepatology
|
2008
|
0.79
|
|
71
|
Results of long-term ursodiol treatment for patients with primary biliary cirrhosis.
|
Am J Gastroenterol
|
2002
|
0.79
|
|
72
|
The spontaneous course of liver enzymes and its correlation in nonalcoholic fatty liver disease.
|
Dig Dis Sci
|
2012
|
0.79
|
|
73
|
Open-label pilot study of folic acid in patients with nonalcoholic steatohepatitis.
|
Liver Int
|
2007
|
0.77
|
|
74
|
Treatment with ursodeoxycholic acid is associated with weight gain in patients with primary biliary cirrhosis.
|
J Clin Gastroenterol
|
2003
|
0.77
|
|
75
|
Right upper-quadrant pain in a patient with drug abuse, secondary syphilis and occult hepatitis B virus.
|
Med Princ Pract
|
2014
|
0.76
|
|
76
|
Moexipril for treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid.
|
Dig Dis Sci
|
2009
|
0.76
|
|
77
|
Treatment of nonalcoholic steatohepatitis: antioxidants or insulin sensitizers?
|
Clin Gastroenterol Hepatol
|
2004
|
0.76
|
|
78
|
Ursodeoxycholic acid and long-term survival in primary biliary cirrhosis.
|
Am J Gastroenterol
|
2004
|
0.75
|
|
79
|
Nonalcoholic fatty liver disease: what are the odds your patient will get a transplant?
|
Clin Gastroenterol Hepatol
|
2011
|
0.75
|
|
80
|
Cryoglobulins in nonalcoholic Fatty-liver disease: what is the association?
|
Gastroenterol Hepatol (N Y)
|
2012
|
0.75
|
|
81
|
The bulge, booze, and the liver.
|
Clin Gastroenterol Hepatol
|
2005
|
0.75
|
|
82
|
[Auto-antibodies in liver disease].
|
Rev Gastroenterol Mex
|
2007
|
0.75
|
|
83
|
Liver-FibroSTARD checklist and glossary: tools for standardized design and reporting of diagnostic accuracy studies of liver fibrosis tests.
|
Clin Chem Lab Med
|
2015
|
0.75
|
|
84
|
Neuroendocrine Liver Metastasis: Transplant as Part of Multimodality Liver-Directed Therapy-Reply.
|
Arch Surg
|
2012
|
0.75
|
|
85
|
Open-label pilot study of tetracycline in the treatment of primary biliary cirrhosis.
|
Am J Gastroenterol
|
2004
|
0.75
|
|
86
|
Oral tolerance and pyruvate dehydrogenase in patients with primary biliary cirrhosis.
|
Dev Immunol
|
2002
|
0.75
|